Stem Cell Transplantation for Children Affected With Osteopetrosis

Study Overview
=================
Brief Summary
-----------------
Malignant infantile osteopetrosis (MIOP) is a rare fatal genetic disorder that is characterized by the bone's inability to regulate remodeling. The only curative therapy is hematopoietic stem cell transplantation. Stem cells provided from an HLA identical matched sibling donor is the standard of care, but not feasible for the majority of patients. In addition, due to the potentially rapid progression of this disease, the time to identify a suitable HLA matched unrelated donor is not optimal. Therefore this study is designed to test the hypothesis that children with osteopetrosis can properly engraft hematopoietic stem cells that are donated from a partially matched parental donor, or haploidentical stem cell donor that are processed on the investigational device, CliniMACS selection system.

Detailed Description
-----------------
The primary objective of this trial will be answered strictly by those patients enrolled who receive a haploidentical stem cell donor graft. Patients with a matched sibling donor will be offered participation in this clinical trial and will receive a standard myeloablative conditioning regimen followed by the infusion of an unmanipulated bone marrow graft. However, data from these transplant recipients will be reported in a descriptive manner only. Secondary Objectives in this trial include the following: To describe the outcome of children with MIOP who receive hematopoietic stem cells from a matched sibling donor or a haploidentical donor utilizing a uniform approach one year from transplant To estimate the fraction of children with MIOP who have a genetic defect correlating to the osteopetrosis phenotype To assess carrier-state of the genetic mutation in parents with an affected child To assess carrier-state of the genetic mutation in siblings of affected children To estimate the effect of age at the time of hematopoietic stem cell transplantation on the overall outcome of children with MIOP To describe the kinetics of select cytokine expression before and after transplantation

Official Title
-----------------
Allogeneic Hematopoietic Stem Cell Transplantation for Children Affected With Malignant Osteopetrosis: A Pilot Study

Conditions
-----------------
Osteopetrosis

Intervention / Treatment
-----------------
* Procedure: Stem Cell Transplantation
* Device: Miltenyi Biotec CliniMACS
* Drug: Systemic chemotherapy and antibodies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of malignant osteopetrosis as documented by bone marrow biopsy and radiographic imaging A suitable hematopoietic stem cell donor is available Exclusion Criteria: Participant has the Carbonic Anhydrase II (CAII) deficiency osteopetrosis variant Symptomatic cardiac disease or evidence of significant cardiac dysfunction by ECHO (shortening fraction <30%) Creatinine clearance ≤ 40ml/min/1.73m^2 Bilirubin ≥ 3mg/dL SGPT ≥ 500 U/L Evidence of current severe infection which would preclude ablative chemotherapy or a successful transplantation Karnofsky or Lansky score < 70 noting expected abnormalities
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br> | Procedure: Stem Cell Transplantation<br>* An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.<br>* Other names: Allogeneic stem cell transplant;Device: Miltenyi Biotec CliniMACS<br>* Stem cell selection device<br>* Other names: T-cell depletion;Drug: Systemic chemotherapy and antibodies<br>* Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis.<br>* Other names: Transplantation for Osteopetrosis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Engraftment | To determine the need for blood or platelet transfusions and the presence of donor cells being present in the transplant recipient's bone marrow or peripheral blood by 100 day after transplantation for children with malignant infantile osteopetrosis who have received a haploidentical stem cell graft. | 100 days post-transplant | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteopetrosis, Autosomal recessive bone disease, Haploidentical stem cell transplantation, Allogeneic stem cell transplantation, T-cell depletion methodology, Miltenyi Biotec CliniMACS stem cell selection device